139 related articles for article (PubMed ID: 11000611)
21. Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines.
Alhamdani MS; Youns M; Buchholz M; Gress TM; Beckers MC; Maréchal D; Bauer A; Schröder C; Hoheisel JD
J Proteomics; 2012 Jun; 75(12):3747-59. PubMed ID: 22579748
[TBL] [Abstract][Full Text] [Related]
22. [Precursors to pancreatic cancer].
Søreide K; Immervoll H; Molven A
Tidsskr Nor Laegeforen; 2006 Mar; 126(7):905-8. PubMed ID: 16554881
[TBL] [Abstract][Full Text] [Related]
23. Identification of potential biomarkers to differentially diagnose solid pseudopapillary tumors and pancreatic malignancies via a gene regulatory network.
Li P; Hu Y; Yi J; Li J; Yang J; Wang J
J Transl Med; 2015 Nov; 13():361. PubMed ID: 26578390
[TBL] [Abstract][Full Text] [Related]
24. The molecular genetics of pancreatic ductal carcinoma.
Sohn TA
Minerva Chir; 2002 Oct; 57(5):561-74. PubMed ID: 12370658
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers of pancreatic cancer.
Hamada S; Shimosegawa T
Pancreatology; 2011; 11 Suppl 2():14-9. PubMed ID: 21464582
[TBL] [Abstract][Full Text] [Related]
26. Molecular genetics of pancreatic intraepithelial neoplasia.
Feldmann G; Beaty R; Hruban RH; Maitra A
J Hepatobiliary Pancreat Surg; 2007; 14(3):224-32. PubMed ID: 17520196
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
28. High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival.
Wang Q; Ni Q; Wang X; Zhu H; Wang Z; Huang J
Med Oncol; 2015 Jan; 32(1):372. PubMed ID: 25428385
[TBL] [Abstract][Full Text] [Related]
29. Nuclear receptors in pancreatic tumor cells.
Damaskos C; Garmpis N; Karatzas T; Kostakis ID; Nikolidakis L; Kostakis A; Kouraklis G
Anticancer Res; 2014 Dec; 34(12):6897-911. PubMed ID: 25503115
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma.
Luo Y; Qiu Z; Tian L; Zhu G; Feng Y; Yi M; Chen X; Wang L; Li C; Huang Q
Hum Pathol; 2013 Jan; 44(1):69-76. PubMed ID: 22939953
[TBL] [Abstract][Full Text] [Related]
31. Molecular diagnosis of pancreatic cancer.
Inoue S; Tezel E; Nakao A
Hepatogastroenterology; 2001; 48(40):933-8. PubMed ID: 11490843
[TBL] [Abstract][Full Text] [Related]
32. Keap1 expression has independent prognostic value in pancreatic adenocarcinomas.
Isohookana J; Haapasaari KM; Soini Y; Karihtala P
Diagn Pathol; 2015 Apr; 10():28. PubMed ID: 25879528
[TBL] [Abstract][Full Text] [Related]
33. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-200c as a Prognostic Biomarker for Pancreatic Cancer.
Paik WH; Song BJ; Kim HW; Kim HR; Hwang JH
Korean J Gastroenterol; 2015 Oct; 66(4):215-20. PubMed ID: 26493507
[TBL] [Abstract][Full Text] [Related]
35. Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact.
Coleman O; Henry M; McVey G; Clynes M; Moriarty M; Meleady P
Expert Rev Proteomics; 2016; 13(4):383-94. PubMed ID: 26985644
[TBL] [Abstract][Full Text] [Related]
36. Current and future biomarkers for pancreatic adenocarcinoma.
Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
38. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma.
Vychytilova-Faltejskova P; Kiss I; Klusova S; Hlavsa J; Prochazka V; Kala Z; Mazanec J; Hausnerova J; Kren L; Hermanova M; Lenz J; Karasek P; Vyzula R; Slaby O
Diagn Pathol; 2015 Apr; 10():38. PubMed ID: 25908274
[TBL] [Abstract][Full Text] [Related]
39. Molecular prognostic factors in patients with pancreatic cancer.
Tonini G; Pantano F; Vincenzi B; Gabbrielli A; Coppola R; Santini D
Expert Opin Ther Targets; 2007 Dec; 11(12):1553-69. PubMed ID: 18020978
[TBL] [Abstract][Full Text] [Related]
40. Semiquantitative immunohistochemistry for mucin (MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance.
Sierzega M; Młynarski D; Tomaszewska R; Kulig J
Histopathology; 2016 Oct; 69(4):582-91. PubMed ID: 27165582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
